Efficacy and safety of bevacizumab plus chemotherapy in chinese patients with metastatic colorectal cancer:A randomized phase iii artist trial

Chinese Journal of Cancer

Volumn 30, Issue 10, 2011, Pages 682-689

  Guan, Zhong Zhen ^a   Xu, Jian Ming ^b   Luo, Rong Cheng ^c   Feng, Feng Yi ^d   Wang, Li Wei ^e   Shen, Lin ^f   Yu, Shi Ying ^g   Ba, Yi ^h   Liang, Jun ⁱ   Wang, Dong ^j   Qin, Shu Kui ^k   Wang, Jie Jun ^l   He, Jing ^m   Qi, Chuan ^m   Xu, Rui Hua ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b Beijing 307 Hospital   (China)

^c FIRST MILITARY MEDICAL UNIVERSITY   (China)

^d CANCER HOSPITAL   (China)

^e SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^f PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^g HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^h TIANJIN MEDICAL UNIVERSITY   (China)

ⁱ QINGDAO UNIVERSITY   (China)

^j THIRD MILITARY MEDICAL UNIVERSITY   (China)

^k The 81 Hospital of Peoples Liberation Army   (China)

^l SECOND MILITARY MEDICAL UNIVERSITY   (China)

^m Roche Product Development in Asia Pacific   (China)

more..

Author keywords

Bevacizumab; Chemotherapy; Chinese patients; First line treatment; Metastatic colorectal cancer

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN;

ADULT; AGED; ANEMIA; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CHINESE; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; WOUND HEALING IMPAIRMENT;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DIARRHEA; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEUTROPENIA; PROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 80054779014     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.011.10188     Document Type: Article

References (17)

1. Globocan 2008. Cancer incidence and mortality worldwide in 2008. Available at: http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=160#BOT H. Accessed on 5th August, 2010.
2. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J]. N Engl J Med, 2004,350(23):2335-2342
3. Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/ leucovorin improves survival for patients with metastatic colorectal cancer [J]. J Clin Oncol, 2005,23(16):3706-3712.
4. Saltz LB, Clarke S, Díaz -Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-lin e therapy in metastatic colorectal cancer: A randomized phase III study [J]. J Clin Oncol, 2008,26(12):2013-2019. Errata in: J Clin Oncol, 2008,26(18):3110; J Clin Oncol, 2009,27(4):653.
5. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200 [J]. J Clin Oncol, 2007,25(12):1539-1544.
6. Kozloff M, Yood MU, Berlin J, et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study [J]. Oncologist, 2009,14(9):862-870.
7. Van Cutsem E, Rivera F, Berry S, et al. Safety and efficacy of first-lin e bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study [J]. Ann Oncol, 2009,20(11):1842-1847.
8. Bekaii-Saab TS, Bendell JC, Cohn AL, et al. Bevacizumab (BV) plus chemotherapy(CT) in second-lin e metastatic colorectal cancer (mCRC): Initial results from ARIES, a second BV observational cohort study (OCS) [J]. J Clin Oncol, 2010, 28 (15s):Abstr 3595. Available at: http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_vi ew&confID=74&abstractID=48372
9. Cohn AL, Bekaii-Saab TS, Bendell JC, et al. Clinical outcomes in bevacizumab(BV)-treated patients(pts) with metastatic colorectal cancer(mCRC): Results from ARIES observational cohort study(OCS) and confirmation of BRiTE data on BV beyond progression(BBP)[J]. J Clin Oncol, 2010, 28 (15s): Abstr 3596. Available at: http://www.asco.org/ascov2/Meetings/ Abstracts? &vmview =abst_detail_view&confID=74&abstractID=44524.
10. Sobrero A, Ackland S, Clarke S, et al. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-lin e metastatic colorectal cancer[J]. Oncology, 2009,77(2):113-119. Errata in: Oncology 2009;77 (2):following 119; Oncology, 2009,77 (3-4):256.
11. Huang Y, Qin SK, Qian J, et al. Clinical study of weekly irinotecan in patients with metastatic colorectal cancer [J]. Cancer Res Prev Treat, 2005,32:110-112. [in Chinese]
12. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-lin e metastatic colorectal cancer [J]. J Clin Oncol, 2005,23(15):3502-3508.
13. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/ leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer [J]. J Clin Oncol, 2003,21(1):60-65.
14. Liévre A, Samalin E, Mitry E, et al. Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-re fractory patients with metastatic colorectal cancer: a retrospective study [J]. BMC Cancer, 2009,9:347.
15. Vincenzi B, Santini D, Russo A, et al. Bevacizumab in association with de Gramont5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-re fractory colorectal cancer: a single-center phase 2 trial[J]. Cancer, 2009,115(20):4849-4856.
16. Yildiz R, Buyukberber S, Uner A, et al. Bevacizumab plus irinotecan-based therapy in metastatic colorectal cancer patients previously treated with oxaliplatin-based regimens [J]. Cancer Invest, 2010,28(1):33-37.
17. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE) [J]. J Clin Oncol, 2008,26 (33):5326-5334.